2021 Revenues ($USD) : $46,385,000,000
2021 R&D spend : $11,354,000,000
2021 Number of Employees : 32,200
Fiscal Year End : 12/31/2021
Leader : CEO Giovanni Caforio

With its roots stretching back to the Squibb corporation founded in 1858, Bristol Myers Squibb now focuses on a variety of therapeutic areas, including oncology, hematology, immunology, cardiovascular and fibrosis. The company sharpened its focus on cardiovascular disease in late 2020 with the $13.1 billion acquisition of MyoKardia. In 2021, sales of the anticoagulant Eliquis and the immunotherapy Opdivo helped fuel growth. Bristol Myers Squibb has accused rivals Merck & Co., Roche and AstraZeneca of patent infringement associated with its immuno-oncology portfolio. —BB